{"id":"sdd-oral-paste","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"SGLT2 inhibitors like SDD Oral Paste work by blocking the reabsorption of glucose in the kidneys, thereby reducing blood glucose levels. This can lead to weight loss and improved cardiovascular outcomes in patients with type 2 diabetes. By inhibiting SGLT2, SDD Oral Paste helps to lower blood glucose levels and improve glycemic control.","oneSentence":"SDD Oral Paste is a drug that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:33:49.189Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT02389036","phase":"PHASE3","title":"Selective Decontamination of the Digestive Tract in Intensive Care Unit Patients","status":"COMPLETED","sponsor":"The George Institute","startDate":"2017-05-01","conditions":"Critical Illness, Sepsis, Septic Shock","enrollment":20010},{"nctId":"NCT02208154","phase":"PHASE3","title":"Ecological Effects of Decolonisation Strategies in Intensive Care","status":"COMPLETED","sponsor":"MJM Bonten","startDate":"2013-12-01","conditions":"ICU-ecology (Multidrug Resistant Bacteria), ICU-acquired Bacteraemia","enrollment":8665},{"nctId":"NCT01761487","phase":"PHASE4","title":"SDD for Eradicating CRKP Carriage","status":"UNKNOWN","sponsor":"Soroka University Medical Center","startDate":"2013-01","conditions":"Carriers of Carbapenem-resistant Klebsiella Pneumonia","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Colistin, Tobramycin and Nystatin"],"phase":"phase_3","status":"active","brandName":"SDD Oral Paste","genericName":"SDD Oral Paste","companyName":"The George Institute","companyId":"the-george-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SDD Oral Paste is a drug that targets the SGLT2 receptor. Used for Treatment of type 2 diabetes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}